DAVID CETOLA

H.R. 965 and S. 340, CREATES Act of 2019, provisions relating to improving the process by which generic drug manufacturers could obtain sufficient quantities of brand drug samples for testing thereby deterring practices that impede generic entry to the market. H.R. 938, BLOCKING Act of 2019, provisions relating to discouraging parking of the 180-day exclusivity period for first generic drug manufacturers challenging pharmaceutical patents. H.R. 3, Lower Drug Costs Now Act of 2019, provisions relating to enhancing first generic drug manufacturers' 180-day exclusivity protections, process improvements and new FDA authority concerning generic drug manufacturers' access to reference samples from branded drug manufacturers, and discouraging parking of the 180-day exclusivity period for first generic drug manufacturers challenging pharmaceutical patents. H.R. 19, Lower Costs, More Cures Act of 2019, provisions relating to enhancing first generic drug manufacturers' 180-day exclusivity protections, process improvements and new FDA authority concerning generic drug manufacturers' access to reference samples from branded drug manufacturers, and discouraging parking of the 180-day exclusivity period for first generic drug manufacturers challenging pharmaceutical patents. S. 1895, Lower Health Care Costs Act of 2019, provisions relating to modifications to the exclusivity benefits afforded to first-to-file generic drug manufacturers.

H.R. 965 and S. 340, CREATES Act of 2019, provisions relating to improving the process by which generic drug manufacturers could obtain sufficient quantities of brand drug samples for testing thereby deterring practices that impede generic entry to the market. H.R. 938, BLOCKING Act of 2019, provisions relating to discouraging parking of the 180-day exclusivity period for first generic drug manufacturers challenging pharmaceutical patents. H.R. 3, Lower Drug Costs Now Act of 2019, provisions relating to enhancing first generic drug manufacturers' 180-day exclusivity protections, process improvements and new FDA authority concerning generic drug manufacturers' access to reference samples from branded drug manufacturers, and discouraging parking of the 180-day exclusivity period for first generic drug manufacturers challenging pharmaceutical patents. H.R. 19, Lower Costs, More Cures Act of 2019, provisions relating to enhancing first generic drug manufacturers' 180-day exclusivity protections, process improvements and new FDA authority concerning generic drug manufacturers' access to reference samples from branded drug manufacturers, and discouraging parking of the 180-day exclusivity period for first generic drug manufacturers challenging pharmaceutical patents. S. 1895, Lower Health Care Costs Act of 2019, provisions relating to modifications to the exclusivity benefits afforded to first-to-file generic drug manufacturers.

Potential bill establishing a DOT grant program relating to national alternative-fueled vehicle charging/fuel corridors and a new commercial truck emissions demonstration program. H.R. 2, the Moving Forward Act, including provisions relating to funding of alternative powertrain recharging infrastructure and incentives for low-emission vehicles.

Potential bill that would revise the federal excise tax on commercial truck purchases based on a truck's performance beyond currently applicable emission standards. S. 1094 and H.R. 2256, Driving America Forward Act, provisions relating to the extension of the electric vehicle tax credit. S. 2289 and H.R. 3961, Renewable Energy Extension Act of 2019, provisions relating to extension of tax incentives associated with fuel cell projects.

H.R. 965 and S. 340, CREATES Act of 2019, provisions relating to improving the process by which generic drug manufacturers could obtain sufficient quantities of brand drug samples for testing thereby deterring practices that impede generic entry to the market. H.R. 938, BLOCKING Act of 2019, provisions relating to discouraging parking of the 180-day exclusivity period for first generic drug manufacturers challenging pharmaceutical patents. H.R. 3, Lower Drug Costs Now Act of 2019, provisions relating to enhancing first generic drug manufacturers' 180-day exclusivity protections, process improvements and new FDA authority concerning generic drug manufacturers' access to reference samples from branded drug manufacturers, and discouraging parking of the 180-day exclusivity period for first generic drug manufacturers challenging pharmaceutical patents. H.R. 19, Lower Costs, More Cures Act of 2019, provisions relating to enhancing first generic drug manufacturers' 180-day exclusivity protections, process improvements and new FDA authority concerning generic drug manufacturers' access to reference samples from branded drug manufacturers, and discouraging parking of the 180-day exclusivity period for first generic drug manufacturers challenging pharmaceutical patents. S. 1895, Lower Health Care Costs Act of 2019, provisions relating to modifications to the exclusivity benefits afforded to first-to-file generic drug manufacturers.

H.R. 965 and S. 340, CREATES Act of 2019, provisions relating to improving the process by which generic drug manufacturers could obtain sufficient quantities of brand drug samples for testing thereby deterring practices that impede generic entry to the market. H.R. 938, BLOCKING Act of 2019, provisions relating to discouraging parking of the 180-day exclusivity period for first generic drug manufacturers challenging pharmaceutical patents. H.R. 3, Lower Drug Costs Now Act of 2019, provisions relating to enhancing first generic drug manufacturers' 180-day exclusivity protections, process improvements and new FDA authority concerning generic drug manufacturers' access to reference samples from branded drug manufacturers, and discouraging parking of the 180-day exclusivity period for first generic drug manufacturers challenging pharmaceutical patents. H.R. 19, Lower Costs, More Cures Act of 2019, provisions relating to enhancing first generic drug manufacturers' 180-day exclusivity protections, process improvements and new FDA authority concerning generic drug manufacturers' access to reference samples from branded drug manufacturers, and discouraging parking of the 180-day exclusivity period for first generic drug manufacturers challenging pharmaceutical patents. S. 1895, Lower Health Care Costs Act of 2019, provisions relating to modifications to the exclusivity benefits afforded to first-to-file generic drug manufacturers.

Potential bill that would revise the federal excise tax on commercial truck purchases based on a truck's performance beyond currently applicable emission standards. S. 1094 and H.R. 2256, Driving America Forward Act, provisions relating to the extension of the electric vehicle tax credit. S. 2289 and H.R. 3961, Renewable Energy Extension Act of 2019, provisions relating to extension of tax incentives associated with fuel cell projects.

H.R. 1865, Further Consolidated Appropriations Act of 2020, FY2020 appropriations provisions relating to the general funding levels of the EPA, delaying implementation of the 2015 Ozone NAAQS, funding regulatory work for EPA's Cleaner Trucks Initiative, extending alternative-fueled vehicle tax credits, funding DOE fuel cell-related research and development programs, enhancing first generic drug manufacturers' 180-day exclusivity protections, and process improvements and new FDA authority concerning generic drug manufacturers' access to reference samples from branded drug manufacturers. H.R. 478, Coronavirus Aid, Relief, and Economic Security Act, provisions relating to drug manufacturers to submit more information when there is an interruption in supply, including information about active pharmaceutical ingredients, when active pharmaceutical ingredients are the cause of the interruption, and potential provisions relating to the modification of China 301 tariffs.

H.R. 1865, Further Consolidated Appropriations Act of 2020, FY2020 appropriations provisions relating to the general funding levels of the EPA, delaying implementation of the 2015 Ozone NAAQS, funding regulatory work for EPA's Cleaner Trucks Initiative, extending alternative-fueled vehicle tax credits, funding DOE fuel cell-related research and development programs, enhancing first generic drug manufacturers' 180-day exclusivity protections, and process improvements and new FDA authority concerning generic drug manufacturers' access to reference samples from branded drug manufacturers. H.R. 478, Coronavirus Aid, Relief, and Economic Security Act, provisions relating to drug manufacturers to submit more information when there is an interruption in supply, including information about active pharmaceutical ingredients, when active pharmaceutical ingredients are the cause of the interruption, and potential provisions relating to the modification of China 301 tariffs.

H.R. 1, For the People Act of 2019, provisions relating to changes to the framework governing commercial lobbying and the definition of "foreign national" for the purposes of participating in the political process. H.R. 5150, Transparency in Government Act of 2019, provisions related to amending the Lobbying Disclosure Act exemption under the Foreign Agents Registration Act. H.R. 5733, Foreign Influence Registration Modernization Act, provisions relating to excluding agents of foreign enterprises that are not under the control or direction of a government of a foreign country or a foreign political party from FARA. S. 1762, Foreign Agents Disclosure and Registration Enhancement Act of 2019, provisions relating to directing the GAO to conduct audits of the use of the LDA exemption and the expansion of the Department of Justice's authority to enforce the Foreign Agents Registration Act and increase noncompliance penalties.

H.R. 1, For the People Act of 2019, provisions relating to changes to the framework governing commercial lobbying and the definition of "foreign national" for the purposes of participating in the political process. H.R. 5150, Transparency in Government Act of 2019, provisions related to amending the Lobbying Disclosure Act exemption under the Foreign Agents Registration Act. H.R. 5733, Foreign Influence Registration Modernization Act, provisions relating to excluding agents of foreign enterprises that are not under the control or direction of a government of a foreign country or a foreign political party from FARA. S. 1762, Foreign Agents Disclosure and Registration Enhancement Act of 2019, provisions relating to directing the GAO to conduct audits of the use of the LDA exemption and the expansion of the Department of Justice's authority to enforce the Foreign Agents Registration Act and increase noncompliance penalties.

H.R. 1, For the People Act of 2019, provisions relating to changes to the framework governing commercial lobbying and the definition of "foreign national" for the purposes of participating in the political process. H.R. 5150, Transparency in Government Act of 2019, provisions related to amending the Lobbying Disclosure Act exemption under the Foreign Agents Registration Act. H.R. 5733, Foreign Influence Registration Modernization Act, provisions relating to excluding agents of foreign enterprises that are not under the control or direction of a government of a foreign country or a foreign political party from FARA. S. 1762, Foreign Agents Disclosure and Registration Enhancement Act of 2019, provisions relating to directing the GAO to conduct audits of the use of the LDA exemption and the expansion of the Department of Justice's authority to enforce the Foreign Agents Registration Act and increase noncompliance penalties.

H.R. 1, For the People Act of 2019, provisions relating to changes to the framework governing commercial lobbying and the definition of "foreign national" for the purposes of participating in the political process. H.R. 5150, Transparency in Government Act of 2019, provisions related to amending the Lobbying Disclosure Act exemption under the Foreign Agents Registration Act. H.R. 5733, Foreign Influence Registration Modernization Act, provisions relating to excluding agents of foreign enterprises that are not under the control or direction of a government of a foreign country or a foreign political party from FARA. S. 1762, Foreign Agents Disclosure and Registration Enhancement Act of 2019, provisions relating to directing the GAO to conduct audits of the use of the LDA exemption and the expansion of the Department of Justice's authority to enforce the Foreign Agents Registration Act and increase noncompliance penalties.

H.R. 965 and S. 340, CREATES Act of 2019, provisions relating to improving the process by which generic drug manufacturers could obtain sufficient quantities of brand drug samples for testing thereby deterring practices that impede generic entry to the market. H.R. 938, BLOCKING Act of 2019, provisions relating to discouraging parking of the 180-day exclusivity period for first generic drug manufacturers challenging pharmaceutical patents. H.R. 3, Lower Drug Costs Now Act of 2019, provisions relating to enhancing first generic drug manufacturers' 180-day exclusivity protections, process improvements and new FDA authority concerning generic drug manufacturers' access to reference samples from branded drug manufacturers, and discouraging parking of the 180-day exclusivity period for first generic drug manufacturers challenging pharmaceutical patents. H.R. 19, Lower Costs, More Cures Act of 2019, provisions relating to enhancing first generic drug manufacturers' 180-day exclusivity protections, process improvements and new FDA authority concerning generic drug manufacturers' access to reference samples from branded drug manufacturers, and discouraging parking of the 180-day exclusivity period for first generic drug manufacturers challenging pharmaceutical patents. S. 1895, Lower Health Care Costs Act of 2019, provisions relating to modifications to the exclusivity benefits afforded to first-to-file generic drug manufacturers.

H.R. 965 and S. 340, CREATES Act of 2019, provisions relating to improving the process by which generic drug manufacturers could obtain sufficient quantities of brand drug samples for testing thereby deterring practices that impede generic entry to the market. H.R. 938, BLOCKING Act of 2019, provisions relating to discouraging parking of the 180-day exclusivity period for first generic drug manufacturers challenging pharmaceutical patents. H.R. 3, Lower Drug Costs Now Act of 2019, provisions relating to enhancing first generic drug manufacturers' 180-day exclusivity protections, process improvements and new FDA authority concerning generic drug manufacturers' access to reference samples from branded drug manufacturers, and discouraging parking of the 180-day exclusivity period for first generic drug manufacturers challenging pharmaceutical patents. H.R. 19, Lower Costs, More Cures Act of 2019, provisions relating to enhancing first generic drug manufacturers' 180-day exclusivity protections, process improvements and new FDA authority concerning generic drug manufacturers' access to reference samples from branded drug manufacturers, and discouraging parking of the 180-day exclusivity period for first generic drug manufacturers challenging pharmaceutical patents. S. 1895, Lower Health Care Costs Act of 2019, provisions relating to modifications to the exclusivity benefits afforded to first-to-file generic drug manufacturers.

H.R. 965 and S. 340, CREATES Act of 2019, provisions relating to improving the process by which generic drug manufacturers could obtain sufficient quantities of brand drug samples for testing thereby deterring practices that impede generic entry to the market. H.R. 938, BLOCKING Act of 2019, provisions relating to discouraging parking of the 180-day exclusivity period for first generic drug manufacturers challenging pharmaceutical patents. H.R. 3, Lower Drug Costs Now Act of 2019, provisions relating to enhancing first generic drug manufacturers' 180-day exclusivity protections, process improvements and new FDA authority concerning generic drug manufacturers' access to reference samples from branded drug manufacturers, and discouraging parking of the 180-day exclusivity period for first generic drug manufacturers challenging pharmaceutical patents. H.R. 19, Lower Costs, More Cures Act of 2019, provisions relating to enhancing first generic drug manufacturers' 180-day exclusivity protections, process improvements and new FDA authority concerning generic drug manufacturers' access to reference samples from branded drug manufacturers, and discouraging parking of the 180-day exclusivity period for first generic drug manufacturers challenging pharmaceutical patents. S. 1895, Lower Health Care Costs Act of 2019, provisions relating to modifications to the exclusivity benefits afforded to first-to-file generic drug manufacturers.

H.R. 965 and S. 340, CREATES Act of 2019, provisions relating to improving the process by which generic drug manufacturers could obtain sufficient quantities of brand drug samples for testing thereby deterring practices that impede generic entry to the market. H.R. 938, BLOCKING Act of 2019, provisions relating to discouraging parking of the 180-day exclusivity period for first generic drug manufacturers challenging pharmaceutical patents. H.R. 3, Lower Drug Costs Now Act of 2019, provisions relating to enhancing first generic drug manufacturers' 180-day exclusivity protections, process improvements and new FDA authority concerning generic drug manufacturers' access to reference samples from branded drug manufacturers, and discouraging parking of the 180-day exclusivity period for first generic drug manufacturers challenging pharmaceutical patents. H.R. 19, Lower Costs, More Cures Act of 2019, provisions relating to enhancing first generic drug manufacturers' 180-day exclusivity protections, process improvements and new FDA authority concerning generic drug manufacturers' access to reference samples from branded drug manufacturers, and discouraging parking of the 180-day exclusivity period for first generic drug manufacturers challenging pharmaceutical patents. S. 1895, Lower Health Care Costs Act of 2019, provisions relating to modifications to the exclusivity benefits afforded to first-to-file generic drug manufacturers.

EPA heavy-duty vehicle criteria pollutant regulation (EPA Cleaner Trucks Initiative). EPA heavy-duty vehicle GHG Phase 2 regulation, provisions relating to glider kits. EPA and NHTSA federal light-duty mobile source regulations, provisions relating to criteria pollutant emission standards, CAFE and greenhouse gas programs, and certification procedures. EPA reconsideration of the 2015 Ozone NAAQS and the 2020 Ozone NAAQS review. H.R. 978, Clean and Efficient Cars Act of 2019, provisions relating to EPA/NHTSA light-duty greenhouse gas and fuel efficiency standards. S. 2302, America's Transportation Infrastructure Act of 2019, provisions relating to Diesel Emissions Reduction Act funding and alternative fuel/recharging infrastructure funding.

EPA heavy-duty vehicle criteria pollutant regulation (EPA Cleaner Trucks Initiative). EPA heavy-duty vehicle GHG Phase 2 regulation, provisions relating to glider kits. EPA and NHTSA federal light-duty mobile source regulations, provisions relating to criteria pollutant emission standards, CAFE and greenhouse gas programs, and certification procedures. EPA reconsideration of the 2015 Ozone NAAQS and the 2020 Ozone NAAQS review. H.R. 978, Clean and Efficient Cars Act of 2019, provisions relating to EPA/NHTSA light-duty greenhouse gas and fuel efficiency standards. S. 2302, America's Transportation Infrastructure Act of 2019, provisions relating to Diesel Emissions Reduction Act funding and alternative fuel/recharging infrastructure funding.

Potential bill that would revise the federal excise tax on commercial truck purchases based on a truck's performance beyond currently applicable emission standards. S. 1094 and H.R. 2256, Driving America Forward Act, provisions relating to the extension of the electric vehicle tax credit. S. 2289 and H.R. 3961, Renewable Energy Extension Act of 2019, provisions relating to extension of tax incentives associated with fuel cell projects.

H.R. 1, For the People Act of 2019, provisions relating to changes to the framework governing commercial lobbying and the definition of "foreign national" for the purposes of participating in the political process. H.R. 5150, Transparency in Government Act of 2019, provisions related to amending the Lobbying Disclosure Act exemption under the Foreign Agents Registration Act. H.R. 5733, Foreign Influence Registration Modernization Act, provisions relating to excluding agents of foreign enterprises that are not under the control or direction of a government of a foreign country or a foreign political party from FARA. S. 1762, Foreign Agents Disclosure and Registration Enhancement Act of 2019, provisions relating to directing the GAO to conduct audits of the use of the LDA exemption and the expansion of the Department of Justice's authority to enforce the Foreign Agents Registration Act and increase noncompliance penalties.

H.R. 1, For the People Act of 2019, provisions relating to changes to the framework governing commercial lobbying and the definition of "foreign national" for the purposes of participating in the political process. H.R. 5150, Transparency in Government Act of 2019, provisions related to amending the Lobbying Disclosure Act exemption under the Foreign Agents Registration Act. H.R. 5733, Foreign Influence Registration Modernization Act, provisions relating to excluding agents of foreign enterprises that are not under the control or direction of a government of a foreign country or a foreign political party from FARA. S. 1762, Foreign Agents Disclosure and Registration Enhancement Act of 2019, provisions relating to directing the GAO to conduct audits of the use of the LDA exemption and the expansion of the Department of Justice's authority to enforce the Foreign Agents Registration Act and increase noncompliance penalties.

H.R. 965 and S. 340, CREATES Act of 2019, provisions relating to improving the process by which generic drug manufacturers could obtain sufficient quantities of brand drug samples for testing thereby deterring practices that impede generic entry to the market. H.R. 938, BLOCKING Act of 2019, provisions relating to discouraging parking of the 180-day exclusivity period for first generic drug manufacturers challenging pharmaceutical patents. H.R. 3, Lower Drug Costs Now Act of 2019, provisions relating to enhancing first generic drug manufacturers' 180-day exclusivity protections, process improvements and new FDA authority concerning generic drug manufacturers' access to reference samples from branded drug manufacturers, and discouraging parking of the 180-day exclusivity period for first generic drug manufacturers challenging pharmaceutical patents. H.R. 19, Lower Costs, More Cures Act of 2019, provisions relating to enhancing first generic drug manufacturers' 180-day exclusivity protections, process improvements and new FDA authority concerning generic drug manufacturers' access to reference samples from branded drug manufacturers, and discouraging parking of the 180-day exclusivity period for first generic drug manufacturers challenging pharmaceutical patents. S. 1895, Lower Health Care Costs Act of 2019, provisions relating to modifications to the exclusivity benefits afforded to first-to-file generic drug manufacturers.

H.R. 965 and S. 340, CREATES Act of 2019, provisions relating to improving the process by which generic drug manufacturers could obtain sufficient quantities of brand drug samples for testing thereby deterring practices that impede generic entry to the market. H.R. 938, BLOCKING Act of 2019, provisions relating to discouraging parking of the 180-day exclusivity period for first generic drug manufacturers challenging pharmaceutical patents. H.R. 3, Lower Drug Costs Now Act of 2019, provisions relating to enhancing first generic drug manufacturers' 180-day exclusivity protections, process improvements and new FDA authority concerning generic drug manufacturers' access to reference samples from branded drug manufacturers, and discouraging parking of the 180-day exclusivity period for first generic drug manufacturers challenging pharmaceutical patents. H.R. 19, Lower Costs, More Cures Act of 2019, provisions relating to enhancing first generic drug manufacturers' 180-day exclusivity protections, process improvements and new FDA authority concerning generic drug manufacturers' access to reference samples from branded drug manufacturers, and discouraging parking of the 180-day exclusivity period for first generic drug manufacturers challenging pharmaceutical patents. S. 1895, Lower Health Care Costs Act of 2019, provisions relating to modifications to the exclusivity benefits afforded to first-to-file generic drug manufacturers.

Potential bill that would revise the federal excise tax on commercial truck purchases based on a truck's performance beyond currently applicable emission standards. S. 1094 and H.R. 2256, Driving America Forward Act, provisions relating to the extension of the electric vehicle tax credit. S. 2289 and H.R. 3961, Renewable Energy Extension Act of 2019, provisions relating to extension of tax incentives associated with fuel cell projects.

EPA heavy-duty vehicle criteria pollutant regulation (EPA Cleaner Trucks Initiative). EPA heavy-duty vehicle GHG Phase 2 regulation, provisions relating to glider kits. EPA and NHTSA federal light-duty mobile source regulations, provisions relating to criteria pollutant emission standards, CAFE and greenhouse gas programs, and certification procedures. EPA reconsideration of the 2015 Ozone NAAQS and the 2020 Ozone NAAQS review. H.R. 978, Clean and Efficient Cars Act of 2019, provisions relating to EPA/NHTSA light-duty greenhouse gas and fuel efficiency standards. S. 2302, America's Transportation Infrastructure Act of 2019, provisions relating to Diesel Emissions Reduction Act funding and alternative fuel/recharging infrastructure funding.

EPA heavy-duty vehicle criteria pollutant regulation (EPA Cleaner Trucks Initiative). EPA heavy-duty vehicle GHG Phase 2 regulation, provisions relating to glider kits. EPA and NHTSA federal light-duty mobile source regulations, provisions relating to criteria pollutant emission standards, CAFE and greenhouse gas programs, and certification procedures. EPA reconsideration of the 2015 Ozone NAAQS and the 2020 Ozone NAAQS review. H.R. 978, Clean and Efficient Cars Act of 2019, provisions relating to EPA/NHTSA light-duty greenhouse gas and fuel efficiency standards. S. 2302, America's Transportation Infrastructure Act of 2019, provisions relating to Diesel Emissions Reduction Act funding and alternative fuel/recharging infrastructure funding.

United States-Mexico-Canada (USMCA); the Uniform Tariff Schedule (UTS), including USTR's s. 301 investigation into China; Department of Commerce's s. 232 Aluminum and Steel investigation, and s. 232 Auto investigation; and potential tariffs on imports from Mexico.

United States-Mexico-Canada (USMCA); the Uniform Tariff Schedule (UTS), including USTR's s. 301 investigation into China; Department of Commerce's s. 232 Aluminum and Steel investigation, and s. 232 Auto investigation; and potential tariffs on imports from Mexico.

S. 2657, American Energy Innovation Act, provisions relating to improving energy efficiency at federal buildings, incentivizing state building energy efficiency, and creating DOE grid storage programs. Potential House bills aimed at incentivizing new technologies aimed at mitigating climate change.

S. 2657, American Energy Innovation Act, provisions relating to improving energy efficiency at federal buildings, incentivizing state building energy efficiency, and creating DOE grid storage programs. Potential House bills aimed at incentivizing new technologies aimed at mitigating climate change.

United States-Mexico-Canada (USMCA); the Uniform Tariff Schedule (UTS), including USTR's s. 301 investigation into China; Department of Commerce's s. 232 Aluminum and Steel investigation, and s. 232 Auto investigation; and potential tariffs on imports from Mexico.

United States-Mexico-Canada (USMCA); the Uniform Tariff Schedule (UTS), including USTR's s. 301 investigation into China; Department of Commerce's s. 232 Aluminum and Steel investigation, and s. 232 Auto investigation; and potential tariffs on imports from Mexico.

H.R. 965 and S. 340, CREATES Act of 2019, provisions relating to improving the process by which generic drug manufacturers could obtain sufficient quantities of brand drug samples for testing thereby deterring practices that impede generic entry to the market. H.R. 938, BLOCKING Act of 2019, provisions relating to discouraging parking of the 180-day exclusivity period for first generic drug manufacturers challenging pharmaceutical patents. H.R. 3, Lower Drug Costs Now Act of 2019, provisions relating to enhancing first generic drug manufacturers' 180-day exclusivity protections, process improvements and new FDA authority concerning generic drug manufacturers' access to reference samples from branded drug manufacturers, and discouraging parking of the 180-day exclusivity period for first generic drug manufacturers challenging pharmaceutical patents. H.R. 19, Lower Costs, More Cures Act of 2019, provisions relating to enhancing first generic drug manufacturers' 180-day exclusivity protections, process improvements and new FDA authority concerning generic drug manufacturers' access to reference samples from branded drug manufacturers, and discouraging parking of the 180-day exclusivity period for first generic drug manufacturers challenging pharmaceutical patents. S. 1895, Lower Health Care Costs Act of 2019, provisions relating to modifications to the exclusivity benefits afforded to first-to-file generic drug manufacturers.

H.R. 965 and S. 340, CREATES Act of 2019, provisions relating to improving the process by which generic drug manufacturers could obtain sufficient quantities of brand drug samples for testing thereby deterring practices that impede generic entry to the market. H.R. 938, BLOCKING Act of 2019, provisions relating to discouraging parking of the 180-day exclusivity period for first generic drug manufacturers challenging pharmaceutical patents. H.R. 3, Lower Drug Costs Now Act of 2019, provisions relating to enhancing first generic drug manufacturers' 180-day exclusivity protections, process improvements and new FDA authority concerning generic drug manufacturers' access to reference samples from branded drug manufacturers, and discouraging parking of the 180-day exclusivity period for first generic drug manufacturers challenging pharmaceutical patents. H.R. 19, Lower Costs, More Cures Act of 2019, provisions relating to enhancing first generic drug manufacturers' 180-day exclusivity protections, process improvements and new FDA authority concerning generic drug manufacturers' access to reference samples from branded drug manufacturers, and discouraging parking of the 180-day exclusivity period for first generic drug manufacturers challenging pharmaceutical patents. S. 1895, Lower Health Care Costs Act of 2019, provisions relating to modifications to the exclusivity benefits afforded to first-to-file generic drug manufacturers.

H.R. 1 For the People Act of 2019, provisions relating to changes to the framework governing commercial lobbying and the definition of "foreign national" for the purposes of participating in the political process. S. 1762 Foreign Agents Disclosure and Registration Enhancement Act of 2019, provisions relating to the expansion of the Department of Justice's authority to enforce the Foreign Agents Registration Act and increase noncompliance penalties.

H.R. 1, For the People Act of 2019, provisions relating to changes to the framework governing commercial lobbying and the definition of "foreign national" for the purposes of participating in the political process. S. 1762, Foreign Agents Disclosure and Registration Enhancement Act of 2019, provisions relating to the expansion of the Department of Justice's authority to enforce the Foreign Agents Registration Act and increase noncompliance penalties.

H.R. 1, For the People Act of 2019, provisions relating to changes to the framework governing commercial lobbying and the definition of "foreign national" for the purposes of participating in the political process. H.R. 5150, Transparency in Government Act of 2019, provisions related to amending the Lobbying Disclosure Act exemption under the Foreign Agents Registration Act. S. 1762, Foreign Agents Disclosure and Registration Enhancement Act of 2019, provisions relating to the expansion of the Department of Justice's authority to enforce the Foreign Agents Registration Act and increase noncompliance penalties.

H.R. 1 For the People Act of 2019, including potential provisions related to changes to the framework governing commercial lobbying and the definition of "foreign national" for the purposes of participating in the political process.

H.R. 88 (115), Taxpayer First Act of 2018, including provisions related to tax credits associated with alternative-fueled vehicles and related refueling infrastructure. H.R. 1027 and S. 343, Fairness to Every Driver Act, including provisions related to tax credits and highway user fees associated with alternative-fueled vehicles.

H.R. 88 (115), Taxpayer First Act of 2018, provisions relating to tax credits associated with alternative-fueled vehicles and related refueling infrastructure. H.R. 1027 and S. 343, Fairness to Every Driver Act, provisions relating to tax credits and highway user fees associated with alternative-fueled vehicles. Potential bill that would revise the federal excise tax on commercial truck purchases based on a truck's performance beyond currently applicable emission standards. S. 1094 Driving America Forward Act, provisions relating to the extension of the electric vehicle tax credit. S. 1288 Clean Energy for America Act, provisions relating to removing caps and extending alternative fuel tax credits.

H.R. 965 and S. 340 CREATES Act of 2019, including provisions related to improving the process by which generic manufacturers could obtain sufficient quantities of brand drug samples for testing thereby deterring practices that impede generic entry to the market. H.R. 938 BLOCKING Act of 2019, including provisions related to discouraging parking of the 180-day exclusivity period for first generic companies challenging pharmaceutical patents. H.R. 990 and S. 344 Hatch-Waxman Integrity Act of 2019, including provisions relating to limit generic companies' ability to initiate inter partes review. H.R. 1520 Purple Book Continuity Act, including provisions relating to codifying publication of patents of approved biological products in the Purple Book in a similar format and with similar requirements to the Orange Book. H.R. 1503 Orange Book Transparency Act, including provisions relating to requiring manufacturers to share complete and timely information with FDA, as well as ensuring that patents listed in the Orange Book are relevant to the approved drug product. H.R. 1499 Protecting Consumer Access to Generic Drugs Act, including provisions relating to the prohibition of agreements between brand drug and generic manufacturers that pay generic manufacturers to keep the generic equivalent off the market. H.R. 1781 Payment Commission Data, including provisions relating to providing drug pricing and rebate data access the Medicare Payment Advisory Commission and Medicaid and CHIP Payment and Access Commission to help these commissions better understand the true costs of prescription drugs to consumers and taxpayers.

H.R. 965 and S. 340 CREATES Act of 2019, provisions relating to improving the process by which generic manufacturers could obtain sufficient quantities of brand drug samples for testing thereby deterring practices that impede generic entry to the market. H.R. 938 BLOCKING Act of 2019, provisions relating to discouraging parking of the 180-day exclusivity period for first generic drugmakers challenging pharmaceutical patents. S. 1895 Lower Health Care Costs Act of 2019, provisions relating to modifications to the exclusivity benefits afforded to first-to-file generic drugmakers. H.R. 990 and S. 344 Hatch-Waxman Integrity Act of 2019, provisions relating to limit generic companies' ability to initiate inter partes review. H.R. 1520 Purple Book Continuity Act, provisions relating to codifying publication of patents of approved biological products in the Purple Book in a similar format and with similar requirements to the Orange Book. H.R. 1503 Orange Book Transparency Act, provisions relating to requiring manufacturers to share complete and timely information with FDA, as well as ensuring that patents listed in the Orange Book are relevant to the approved drug product. H.R. 1499 Protecting Consumer Access to Generic Drugs Act, provisions relating to the prohibition of agreements between brand drug and generic manufacturers that pay generic manufacturers to keep the generic equivalent off the market. H.R. 1781 Payment Commission Data, provisions relating to providing drug pricing and rebate data access the Medicare Payment Advisory Commission and Medicaid and CHIP Payment and Access Commission to help these commissions better understand the true costs of prescription drugs to consumers and taxpayers.

H.R. 965 and S. 340 CREATES Act of 2019, including provisions related to improving the process by which generic manufacturers could obtain sufficient quantities of brand drug samples for testing thereby deterring practices that impede generic entry to the market. H.R. 938 BLOCKING Act of 2019, including provisions related to discouraging parking of the 180-day exclusivity period for first generic companies challenging pharmaceutical patents. H.R. 990 and S. 344 Hatch-Waxman Integrity Act of 2019, including provisions relating to limit generic companies' ability to initiate inter partes review. H.R. 1520 Purple Book Continuity Act, including provisions relating to codifying publication of patents of approved biological products in the Purple Book in a similar format and with similar requirements to the Orange Book. H.R. 1503 Orange Book Transparency Act, including provisions relating to requiring manufacturers to share complete and timely information with FDA, as well as ensuring that patents listed in the Orange Book are relevant to the approved drug product. H.R. 1499 Protecting Consumer Access to Generic Drugs Act, including provisions relating to the prohibition of agreements between brand drug and generic manufacturers that pay generic manufacturers to keep the generic equivalent off the market. H.R. 1781 Payment Commission Data, including provisions relating to providing drug pricing and rebate data access the Medicare Payment Advisory Commission and Medicaid and CHIP Payment and Access Commission to help these commissions better understand the true costs of prescription drugs to consumers and taxpayers.

H.R. 965 and S. 340 CREATES Act of 2019, provisions relating to improving the process by which generic manufacturers could obtain sufficient quantities of brand drug samples for testing thereby deterring practices that impede generic entry to the market. H.R. 938 BLOCKING Act of 2019, provisions relating to discouraging parking of the 180-day exclusivity period for first generic drugmakers challenging pharmaceutical patents. S. 1895 Lower Health Care Costs Act of 2019, provisions relating to modifications to the exclusivity benefits afforded to first-to-file generic drugmakers. H.R. 990 and S. 344 Hatch-Waxman Integrity Act of 2019, provisions relating to limit generic companies' ability to initiate inter partes review. H.R. 1520 Purple Book Continuity Act, provisions relating to codifying publication of patents of approved biological products in the Purple Book in a similar format and with similar requirements to the Orange Book. H.R. 1503 Orange Book Transparency Act, provisions relating to requiring manufacturers to share complete and timely information with FDA, as well as ensuring that patents listed in the Orange Book are relevant to the approved drug product. H.R. 1499 Protecting Consumer Access to Generic Drugs Act, provisions relating to the prohibition of agreements between brand drug and generic manufacturers that pay generic manufacturers to keep the generic equivalent off the market. H.R. 1781 Payment Commission Data, provisions relating to providing drug pricing and rebate data access the Medicare Payment Advisory Commission and Medicaid and CHIP Payment and Access Commission to help these commissions better understand the true costs of prescription drugs to consumers and taxpayers.

H.R. 965 and S. 340 CREATES Act of 2019, including provisions related to improving the process by which generic manufacturers could obtain sufficient quantities of brand drug samples for testing thereby deterring practices that impede generic entry to the market. H.R. 938 BLOCKING Act of 2019, including provisions related to discouraging parking of the 180-day exclusivity period for first generic companies challenging pharmaceutical patents. H.R. 990 and S. 344 Hatch-Waxman Integrity Act of 2019, including provisions relating to limit generic companies' ability to initiate inter partes review. H.R. 1520 Purple Book Continuity Act, including provisions relating to codifying publication of patents of approved biological products in the Purple Book in a similar format and with similar requirements to the Orange Book. H.R. 1503 Orange Book Transparency Act, including provisions relating to requiring manufacturers to share complete and timely information with FDA, as well as ensuring that patents listed in the Orange Book are relevant to the approved drug product. H.R. 1499 Protecting Consumer Access to Generic Drugs Act, including provisions relating to the prohibition of agreements between brand drug and generic manufacturers that pay generic manufacturers to keep the generic equivalent off the market. H.R. 1781 Payment Commission Data, including provisions relating to providing drug pricing and rebate data access the Medicare Payment Advisory Commission and Medicaid and CHIP Payment and Access Commission to help these commissions better understand the true costs of prescription drugs to consumers and taxpayers.

H.R. 965 and S. 340 CREATES Act of 2019, provisions relating to improving the process by which generic manufacturers could obtain sufficient quantities of brand drug samples for testing thereby deterring practices that impede generic entry to the market. H.R. 938 BLOCKING Act of 2019, provisions relating to discouraging parking of the 180-day exclusivity period for first generic drugmakers challenging pharmaceutical patents. S. 1895 Lower Health Care Costs Act of 2019, provisions relating to modifications to the exclusivity benefits afforded to first-to-file generic drugmakers. H.R. 990 and S. 344 Hatch-Waxman Integrity Act of 2019, provisions relating to limit generic companies' ability to initiate inter partes review. H.R. 1520 Purple Book Continuity Act, provisions relating to codifying publication of patents of approved biological products in the Purple Book in a similar format and with similar requirements to the Orange Book. H.R. 1503 Orange Book Transparency Act, provisions relating to requiring manufacturers to share complete and timely information with FDA, as well as ensuring that patents listed in the Orange Book are relevant to the approved drug product. H.R. 1499 Protecting Consumer Access to Generic Drugs Act, provisions relating to the prohibition of agreements between brand drug and generic manufacturers that pay generic manufacturers to keep the generic equivalent off the market. H.R. 1781 Payment Commission Data, provisions relating to providing drug pricing and rebate data access the Medicare Payment Advisory Commission and Medicaid and CHIP Payment and Access Commission to help these commissions better understand the true costs of prescription drugs to consumers and taxpayers.

H.R. 965 and S. 340 CREATES Act of 2019, including provisions related to improving the process by which generic manufacturers could obtain sufficient quantities of brand drug samples for testing thereby deterring practices that impede generic entry to the market. H.R. 938 BLOCKING Act of 2019, including provisions related to discouraging parking of the 180-day exclusivity period for first generic companies challenging pharmaceutical patents. H.R. 990 and S. 344 Hatch-Waxman Integrity Act of 2019, including provisions relating to limit generic companies' ability to initiate inter partes review. H.R. 1520 Purple Book Continuity Act, including provisions relating to codifying publication of patents of approved biological products in the Purple Book in a similar format and with similar requirements to the Orange Book. H.R. 1503 Orange Book Transparency Act, including provisions relating to requiring manufacturers to share complete and timely information with FDA, as well as ensuring that patents listed in the Orange Book are relevant to the approved drug product. H.R. 1499 Protecting Consumer Access to Generic Drugs Act, including provisions relating to the prohibition of agreements between brand drug and generic manufacturers that pay generic manufacturers to keep the generic equivalent off the market. H.R. 1781 Payment Commission Data, including provisions relating to providing drug pricing and rebate data access the Medicare Payment Advisory Commission and Medicaid and CHIP Payment and Access Commission to help these commissions better understand the true costs of prescription drugs to consumers and taxpayers.

H.R. 965 and S. 340 CREATES Act of 2019, provisions relating to improving the process by which generic manufacturers could obtain sufficient quantities of brand drug samples for testing thereby deterring practices that impede generic entry to the market. H.R. 938 BLOCKING Act of 2019, provisions relating to discouraging parking of the 180-day exclusivity period for first generic drugmakers challenging pharmaceutical patents. S. 1895 Lower Health Care Costs Act of 2019, provisions relating to modifications to the exclusivity benefits afforded to first-to-file generic drugmakers. H.R. 990 and S. 344 Hatch-Waxman Integrity Act of 2019, provisions relating to limit generic companies' ability to initiate inter partes review. H.R. 1520 Purple Book Continuity Act, provisions relating to codifying publication of patents of approved biological products in the Purple Book in a similar format and with similar requirements to the Orange Book. H.R. 1503 Orange Book Transparency Act, provisions relating to requiring manufacturers to share complete and timely information with FDA, as well as ensuring that patents listed in the Orange Book are relevant to the approved drug product. H.R. 1499 Protecting Consumer Access to Generic Drugs Act, provisions relating to the prohibition of agreements between brand drug and generic manufacturers that pay generic manufacturers to keep the generic equivalent off the market. H.R. 1781 Payment Commission Data, provisions relating to providing drug pricing and rebate data access the Medicare Payment Advisory Commission and Medicaid and CHIP Payment and Access Commission to help these commissions better understand the true costs of prescription drugs to consumers and taxpayers.

H.R. 1865, Further Consolidated Appropriations Act of 2020, FY2020 appropriations provisions relating to the general funding levels of the EPA, delaying implementation of the 2015 Ozone NAAQS, funding regulatory work for EPA's Cleaner Trucks Initiative, extending alternative-fueled vehicle tax credits, funding DOE fuel cell-related research and development programs, enhancing first generic drug manufacturers' 180-day exclusivity protections, and process improvements and new FDA authority concerning generic drug manufacturers' access to reference samples from branded drug manufacturers.

H.R. 965 and S. 340, CREATES Act of 2019, provisions relating to improving the process by which generic drug manufacturers could obtain sufficient quantities of brand drug samples for testing thereby deterring practices that impede generic entry to the market. H.R. 938, BLOCKING Act of 2019, provisions relating to discouraging parking of the 180-day exclusivity period for first generic drug manufacturers challenging pharmaceutical patents. H.R. 3, Lower Drug Costs Now Act of 2019, provisions relating to enhancing first generic drug manufacturers' 180-day exclusivity protections, process improvements and new FDA authority concerning generic drug manufacturers' access to reference samples from branded drug manufacturers, and discouraging parking of the 180-day exclusivity period for first generic drug manufacturers challenging pharmaceutical patents. H.R. 19, Lower Costs, More Cures Act of 2019, provisions relating to enhancing first generic drug manufacturers' 180-day exclusivity protections, process improvements and new FDA authority concerning generic drug manufacturers' access to reference samples from branded drug manufacturers, and discouraging parking of the 180-day exclusivity period for first generic drug manufacturers challenging pharmaceutical patents. S. 1895, Lower Health Care Costs Act of 2019, provisions relating to modifications to the exclusivity benefits afforded to first-to-file generic drug manufacturers.

Potential bill that would revise the federal excise tax on commercial truck purchases based on a truck's performance beyond currently applicable emission standards. S. 1094 and H.R. 2256, Driving America Forward Act, provisions relating to the extension of the electric vehicle tax credit. S. 2289 and H.R. 3961, Renewable Energy Extension Act of 2019, provisions relating to extension of tax incentives associated with fuel cell projects.

H.R. 965 and S. 340, CREATES Act of 2019, provisions relating to improving the process by which generic drug manufacturers could obtain sufficient quantities of brand drug samples for testing thereby deterring practices that impede generic entry to the market. H.R. 938, BLOCKING Act of 2019, provisions relating to discouraging parking of the 180-day exclusivity period for first generic drug manufacturers challenging pharmaceutical patents. H.R. 3, Lower Drug Costs Now Act of 2019, provisions relating to enhancing first generic drug manufacturers' 180-day exclusivity protections, process improvements and new FDA authority concerning generic drug manufacturers' access to reference samples from branded drug manufacturers, and discouraging parking of the 180-day exclusivity period for first generic drug manufacturers challenging pharmaceutical patents. H.R. 19, Lower Costs, More Cures Act of 2019, provisions relating to enhancing first generic drug manufacturers' 180-day exclusivity protections, process improvements and new FDA authority concerning generic drug manufacturers' access to reference samples from branded drug manufacturers, and discouraging parking of the 180-day exclusivity period for first generic drug manufacturers challenging pharmaceutical patents. S. 1895, Lower Health Care Costs Act of 2019, provisions relating to modifications to the exclusivity benefits afforded to first-to-file generic drug manufacturers.

Potential bill that would revise the federal excise tax on commercial truck purchases based on a truck's performance beyond currently applicable emission standards. S. 1094 and H.R. 2256, Driving America Forward Act, provisions relating to the extension of the electric vehicle tax credit. S. 2289 and H.R. 3961, Renewable Energy Extension Act of 2019, provisions relating to extension of tax incentives associated with fuel cell projects.

H.R. 1, For the People Act of 2019, provisions relating to changes to the framework governing commercial lobbying and the definition of "foreign national" for the purposes of participating in the political process. H.R. 5150, Transparency in Government Act of 2019, provisions related to amending the Lobbying Disclosure Act exemption under the Foreign Agents Registration Act. S. 1762, Foreign Agents Disclosure and Registration Enhancement Act of 2019, provisions relating to the expansion of the Department of Justice's authority to enforce the Foreign Agents Registration Act and increase noncompliance penalties.

H.R. 88 (115), Taxpayer First Act of 2018, including provisions related to tax credits associated with alternative-fueled vehicles and related refueling infrastructure. H.R. 1027 and S. 343, Fairness to Every Driver Act, including provisions related to tax credits and highway user fees associated with alternative-fueled vehicles.

H.R. 88 (115), Taxpayer First Act of 2018, provisions relating to tax credits associated with alternative-fueled vehicles and related refueling infrastructure. H.R. 1027 and S. 343, Fairness to Every Driver Act, provisions relating to tax credits and highway user fees associated with alternative-fueled vehicles. Potential bill that would revise the federal excise tax on commercial truck purchases based on a truck's performance beyond currently applicable emission standards. S. 1094 Driving America Forward Act, provisions relating to the extension of the electric vehicle tax credit. S. 1288 Clean Energy for America Act, provisions relating to removing caps and extending alternative fuel tax credits.

H.R. 965 and S. 340 CREATES Act of 2019, provisions relating to improving the process by which generic manufacturers could obtain sufficient quantities of brand drug samples for testing thereby deterring practices that impede generic entry to the market. H.R. 938 BLOCKING Act of 2019, provisions relating to discouraging parking of the 180-day exclusivity period for first generic drugmakers challenging pharmaceutical patents. S. 1895 Lower Health Care Costs Act of 2019, provisions relating to modifications to the exclusivity benefits afforded to first-to-file generic drugmakers. H.R. 990 and S. 344 Hatch-Waxman Integrity Act of 2019, provisions relating to limit generic companies' ability to initiate inter partes review. H.R. 1520 Purple Book Continuity Act, provisions relating to codifying publication of patents of approved biological products in the Purple Book in a similar format and with similar requirements to the Orange Book. H.R. 1503 Orange Book Transparency Act, provisions relating to requiring manufacturers to share complete and timely information with FDA, as well as ensuring that patents listed in the Orange Book are relevant to the approved drug product. H.R. 1499 Protecting Consumer Access to Generic Drugs Act, provisions relating to the prohibition of agreements between brand drug and generic manufacturers that pay generic manufacturers to keep the generic equivalent off the market. H.R. 1781 Payment Commission Data, provisions relating to providing drug pricing and rebate data access the Medicare Payment Advisory Commission and Medicaid and CHIP Payment and Access Commission to help these commissions better understand the true costs of prescription drugs to consumers and taxpayers.

H.R. 965 and S. 340 CREATES Act of 2019, including provisions related to improving the process by which generic manufacturers could obtain sufficient quantities of brand drug samples for testing thereby deterring practices that impede generic entry to the market. H.R. 938 BLOCKING Act of 2019, including provisions related to discouraging parking of the 180-day exclusivity period for first generic companies challenging pharmaceutical patents. H.R. 990 and S. 344 Hatch-Waxman Integrity Act of 2019, including provisions relating to limit generic companies' ability to initiate inter partes review. H.R. 1520 Purple Book Continuity Act, including provisions relating to codifying publication of patents of approved biological products in the Purple Book in a similar format and with similar requirements to the Orange Book. H.R. 1503 Orange Book Transparency Act, including provisions relating to requiring manufacturers to share complete and timely information with FDA, as well as ensuring that patents listed in the Orange Book are relevant to the approved drug product. H.R. 1499 Protecting Consumer Access to Generic Drugs Act, including provisions relating to the prohibition of agreements between brand drug and generic manufacturers that pay generic manufacturers to keep the generic equivalent off the market. H.R. 1781 Payment Commission Data, including provisions relating to providing drug pricing and rebate data access the Medicare Payment Advisory Commission and Medicaid and CHIP Payment and Access Commission to help these commissions better understand the true costs of prescription drugs to consumers and taxpayers.

H.R. 965 and S. 340, CREATES Act of 2019, provisions relating to improving the process by which generic manufacturers could obtain sufficient quantities of brand drug samples for testing thereby deterring practices that impede generic entry to the market. H.R. 938, BLOCKING Act of 2019, provisions relating to discouraging parking of the 180-day exclusivity period for first generic drugmakers challenging pharmaceutical patents. S. 1895, Lower Health Care Costs Act of 2019, provisions relating to modifications to the exclusivity benefits afforded to first-to-file generic drugmakers.

H.R. 965 and S. 340, CREATES Act of 2019, provisions relating to improving the process by which generic drug manufacturers could obtain sufficient quantities of brand drug samples for testing thereby deterring practices that impede generic entry to the market. H.R. 938, BLOCKING Act of 2019, provisions relating to discouraging parking of the 180-day exclusivity period for first generic drug manufacturers challenging pharmaceutical patents. H.R. 3, Lower Drug Costs Now Act of 2019, provisions relating to enhancing first generic drug manufacturers' 180-day exclusivity protections, process improvements and new FDA authority concerning generic drug manufacturers' access to reference samples from branded drug manufacturers, and discouraging parking of the 180-day exclusivity period for first generic drug manufacturers challenging pharmaceutical patents. H.R. 19, Lower Costs, More Cures Act of 2019, provisions relating to enhancing first generic drug manufacturers' 180-day exclusivity protections, process improvements and new FDA authority concerning generic drug manufacturers' access to reference samples from branded drug manufacturers, and discouraging parking of the 180-day exclusivity period for first generic drug manufacturers challenging pharmaceutical patents. S. 1895, Lower Health Care Costs Act of 2019, provisions relating to modifications to the exclusivity benefits afforded to first-to-file generic drug manufacturers.

H.R. 965 and S. 340 CREATES Act of 2019, provisions relating to improving the process by which generic manufacturers could obtain sufficient quantities of brand drug samples for testing thereby deterring practices that impede generic entry to the market. H.R. 938 BLOCKING Act of 2019, provisions relating to discouraging parking of the 180-day exclusivity period for first generic drugmakers challenging pharmaceutical patents. S. 1895 Lower Health Care Costs Act of 2019, provisions relating to modifications to the exclusivity benefits afforded to first-to-file generic drugmakers. H.R. 990 and S. 344 Hatch-Waxman Integrity Act of 2019, provisions relating to limit generic companies' ability to initiate inter partes review. H.R. 1520 Purple Book Continuity Act, provisions relating to codifying publication of patents of approved biological products in the Purple Book in a similar format and with similar requirements to the Orange Book. H.R. 1503 Orange Book Transparency Act, provisions relating to requiring manufacturers to share complete and timely information with FDA, as well as ensuring that patents listed in the Orange Book are relevant to the approved drug product. H.R. 1499 Protecting Consumer Access to Generic Drugs Act, provisions relating to the prohibition of agreements between brand drug and generic manufacturers that pay generic manufacturers to keep the generic equivalent off the market. H.R. 1781 Payment Commission Data, provisions relating to providing drug pricing and rebate data access the Medicare Payment Advisory Commission and Medicaid and CHIP Payment and Access Commission to help these commissions better understand the true costs of prescription drugs to consumers and taxpayers.

H.R. 965 and S. 340 CREATES Act of 2019, including provisions related to improving the process by which generic manufacturers could obtain sufficient quantities of brand drug samples for testing thereby deterring practices that impede generic entry to the market. H.R. 938 BLOCKING Act of 2019, including provisions related to discouraging parking of the 180-day exclusivity period for first generic companies challenging pharmaceutical patents. H.R. 990 and S. 344 Hatch-Waxman Integrity Act of 2019, including provisions relating to limit generic companies' ability to initiate inter partes review. H.R. 1520 Purple Book Continuity Act, including provisions relating to codifying publication of patents of approved biological products in the Purple Book in a similar format and with similar requirements to the Orange Book. H.R. 1503 Orange Book Transparency Act, including provisions relating to requiring manufacturers to share complete and timely information with FDA, as well as ensuring that patents listed in the Orange Book are relevant to the approved drug product. H.R. 1499 Protecting Consumer Access to Generic Drugs Act, including provisions relating to the prohibition of agreements between brand drug and generic manufacturers that pay generic manufacturers to keep the generic equivalent off the market. H.R. 1781 Payment Commission Data, including provisions relating to providing drug pricing and rebate data access the Medicare Payment Advisory Commission and Medicaid and CHIP Payment and Access Commission to help these commissions better understand the true costs of prescription drugs to consumers and taxpayers.

H.R. 965 and S. 340, CREATES Act of 2019, provisions relating to improving the process by which generic manufacturers could obtain sufficient quantities of brand drug samples for testing thereby deterring practices that impede generic entry to the market. H.R. 938, BLOCKING Act of 2019, provisions relating to discouraging parking of the 180-day exclusivity period for first generic drugmakers challenging pharmaceutical patents. S. 1895, Lower Health Care Costs Act of 2019, provisions relating to modifications to the exclusivity benefits afforded to first-to-file generic drugmakers.

H.R. 965 and S. 340, CREATES Act of 2019, provisions relating to improving the process by which generic drug manufacturers could obtain sufficient quantities of brand drug samples for testing thereby deterring practices that impede generic entry to the market. H.R. 938, BLOCKING Act of 2019, provisions relating to discouraging parking of the 180-day exclusivity period for first generic drug manufacturers challenging pharmaceutical patents. H.R. 3, Lower Drug Costs Now Act of 2019, provisions relating to enhancing first generic drug manufacturers' 180-day exclusivity protections, process improvements and new FDA authority concerning generic drug manufacturers' access to reference samples from branded drug manufacturers, and discouraging parking of the 180-day exclusivity period for first generic drug manufacturers challenging pharmaceutical patents. H.R. 19, Lower Costs, More Cures Act of 2019, provisions relating to enhancing first generic drug manufacturers' 180-day exclusivity protections, process improvements and new FDA authority concerning generic drug manufacturers' access to reference samples from branded drug manufacturers, and discouraging parking of the 180-day exclusivity period for first generic drug manufacturers challenging pharmaceutical patents. S. 1895, Lower Health Care Costs Act of 2019, provisions relating to modifications to the exclusivity benefits afforded to first-to-file generic drug manufacturers.

EPA heavy-duty vehicle criteria pollutant regulation (EPA Cleaner Trucks Initiative). EPA heavy-duty vehicle GHG Phase 2 regulation, provisions relating to glider kits. EPA and NHTSA federal light-duty mobile source regulations, provisions relating to criteria pollutant emission standards, CAFE and greenhouse gas programs, and certification procedures. EPA reconsideration of the 2015 Ozone NAAQS and the 2020 Ozone NAAQS review. H.R. 978, Clean and Efficient Cars Act of 2019, provisions relating to EPA/NHTSA light-duty greenhouse gas and fuel efficiency standards. H.R. 3314, 100 by '50 Act, provisions relating to low-emission commercial truck incentives. S. 92, Regulations from the Executive in Need of Scrutiny Act of 2019, provisions relating to regulatory reform of the Administrative Procedures Act. S. 2302, America's Transportation Infrastructure Act of 2019, provisions relating to Diesel Emissions Reduction Act funding and alternative fuel/recharging infrastructure funding.

EPA heavy-duty vehicle criteria pollutant regulation (EPA Cleaner Trucks Initiative). EPA heavy-duty vehicle GHG Phase 2 regulation, including provisions related to glider kits. EPA and NHTSA federal light-duty mobile source regulations, including policy provisions related to criteria pollutants, CAFE and greenhouse gas programs, and certification procedures. EPA reconsideration of the 2015 Ozone NAAQS and the 2020 Ozone NAAQS review. H.R. 978 Clean and Efficient Cars Act of 2019, including provisions related to EPA/NHTSA light-duty greenhouse gas and fuel efficiency standards. S. 92 Regulations from the Executive in Need of Scrutiny Act of 2019, including provisions related to regulatory reform of the Administrative Procedures Act.

EPA heavy-duty vehicle criteria pollutant regulation (EPA Cleaner Trucks Initiative). EPA heavy-duty vehicle GHG Phase 2 regulation, provisions relating to glider kits. EPA and NHTSA federal light-duty mobile source regulations, provisions relating to criteria pollutant emission standards, CAFE and greenhouse gas programs, and certification procedures. EPA reconsideration of the 2015 Ozone NAAQS and the 2020 Ozone NAAQS review. H.R. 978 Clean and Efficient Cars Act of 2019, provisions relating to EPA/NHTSA light-duty greenhouse gas and fuel efficiency standards. S. 92, Regulations from the Executive in Need of Scrutiny Act of 2019, provisions relating to regulatory reform of the Administrative Procedures Act. S. 2302, America's Transportation Infrastructure Act of 2019, provisions relating to Diesel Emissions Reduction Act funding and alternative fuel/recharging infrastructure funding.

EPA heavy-duty vehicle criteria pollutant regulation (EPA Cleaner Trucks Initiative). EPA heavy-duty vehicle GHG Phase 2 regulation, provisions relating to glider kits. EPA and NHTSA federal light-duty mobile source regulations, provisions relating to criteria pollutant emission standards, CAFE and greenhouse gas programs, and certification procedures. EPA reconsideration of the 2015 Ozone NAAQS and the 2020 Ozone NAAQS review. H.R. 978 Clean and Efficient Cars Act of 2019, provisions relating to EPA/NHTSA light-duty greenhouse gas and fuel efficiency standards. S. 92 Regulations from the Executive in Need of Scrutiny Act of 2019, provisions relating to regulatory reform of the Administrative Procedures Act.

H.R. 965 and S. 340 CREATES Act of 2019, provisions relating to improving the process by which generic manufacturers could obtain sufficient quantities of brand drug samples for testing thereby deterring practices that impede generic entry to the market. H.R. 938 BLOCKING Act of 2019, provisions relating to discouraging parking of the 180-day exclusivity period for first generic drugmakers challenging pharmaceutical patents. S. 1895 Lower Health Care Costs Act of 2019, provisions relating to modifications to the exclusivity benefits afforded to first-to-file generic drugmakers. H.R. 990 and S. 344 Hatch-Waxman Integrity Act of 2019, provisions relating to limit generic companies' ability to initiate inter partes review. H.R. 1520 Purple Book Continuity Act, provisions relating to codifying publication of patents of approved biological products in the Purple Book in a similar format and with similar requirements to the Orange Book. H.R. 1503 Orange Book Transparency Act, provisions relating to requiring manufacturers to share complete and timely information with FDA, as well as ensuring that patents listed in the Orange Book are relevant to the approved drug product. H.R. 1499 Protecting Consumer Access to Generic Drugs Act, provisions relating to the prohibition of agreements between brand drug and generic manufacturers that pay generic manufacturers to keep the generic equivalent off the market. H.R. 1781 Payment Commission Data, provisions relating to providing drug pricing and rebate data access the Medicare Payment Advisory Commission and Medicaid and CHIP Payment and Access Commission to help these commissions better understand the true costs of prescription drugs to consumers and taxpayers.

H.R. 965 and S. 340 CREATES Act of 2019, including provisions related to improving the process by which generic manufacturers could obtain sufficient quantities of brand drug samples for testing thereby deterring practices that impede generic entry to the market. H.R. 938 BLOCKING Act of 2019, including provisions related to discouraging parking of the 180-day exclusivity period for first generic companies challenging pharmaceutical patents. H.R. 990 and S. 344 Hatch-Waxman Integrity Act of 2019, including provisions relating to limit generic companies' ability to initiate inter partes review. H.R. 1520 Purple Book Continuity Act, including provisions relating to codifying publication of patents of approved biological products in the Purple Book in a similar format and with similar requirements to the Orange Book. H.R. 1503 Orange Book Transparency Act, including provisions relating to requiring manufacturers to share complete and timely information with FDA, as well as ensuring that patents listed in the Orange Book are relevant to the approved drug product. H.R. 1499 Protecting Consumer Access to Generic Drugs Act, including provisions relating to the prohibition of agreements between brand drug and generic manufacturers that pay generic manufacturers to keep the generic equivalent off the market. H.R. 1781 Payment Commission Data, including provisions relating to providing drug pricing and rebate data access the Medicare Payment Advisory Commission and Medicaid and CHIP Payment and Access Commission to help these commissions better understand the true costs of prescription drugs to consumers and taxpayers.

Potential bill that would revise the federal excise tax on commercial truck purchases based on a truck's performance beyond currently applicable emission standards. S. 1094, Driving America Forward Act, provisions relating to the extension of the electric vehicle tax credit.

H.R. 88 (115), Taxpayer First Act of 2018, provisions relating to tax credits associated with alternative-fueled vehicles and related refueling infrastructure. H.R. 1027 and S. 343, Fairness to Every Driver Act, provisions relating to tax credits and highway user fees associated with alternative-fueled vehicles. Potential bill that would revise the federal excise tax on commercial truck purchases based on a truck's performance beyond currently applicable emission standards. S. 1094 Driving America Forward Act, provisions relating to the extension of the electric vehicle tax credit. S. 1288 Clean Energy for America Act, provisions relating to removing caps and extending alternative fuel tax credits.

Potential bill that would revise the federal excise tax on commercial truck purchases based on a truck's performance beyond currently applicable emission standards. S. 1094 and H.R. 2256, Driving America Forward Act, provisions relating to the extension of the electric vehicle tax credit. S. 2289 and H.R. 3961, Renewable Energy Extension Act of 2019, provisions relating to extension of tax incentives associated with fuel cell projects.

H.R. 88 (115), Taxpayer First Act of 2018, provisions relating to tax credits associated with alternative-fueled vehicles and related refueling infrastructure. H.R. 1027 and S. 343, Fairness to Every Driver Act, provisions relating to tax credits and highway user fees associated with alternative-fueled vehicles. Potential bill that would revise the federal excise tax on commercial truck purchases based on a truck's performance beyond currently applicable emission standards. S. 1094 Driving America Forward Act, provisions relating to the extension of the electric vehicle tax credit. S. 1288 Clean Energy for America Act, provisions relating to removing caps and extending alternative fuel tax credits.

S. 1317 American Mineral Security Act, provisions relating to promotion of US mining and processing of critical minerals.

H.R. 1 For the People Act of 2019, provisions relating to changes to the framework governing commercial lobbying and the definition of "foreign national" for the purposes of participating in the political process. S. 1762 Foreign Agents Disclosure and Registration Enhancement Act of 2019, provisions relating to the expansion of the Department of Justice's authority to enforce the Foreign Agents Registration Act and increase noncompliance penalties.

H.R. 1, For the People Act of 2019, provisions relating to changes to the framework governing commercial lobbying and the definition of "foreign national" for the purposes of participating in the political process. S. 1762, Foreign Agents Disclosure and Registration Enhancement Act of 2019, provisions relating to the expansion of the Department of Justice's authority to enforce the Foreign Agents Registration Act and increase noncompliance penalties.

H.R. 1, For the People Act of 2019, provisions relating to changes to the framework governing commercial lobbying and the definition of "foreign national" for the purposes of participating in the political process. H.R. 5150, Transparency in Government Act of 2019, provisions related to amending the Lobbying Disclosure Act exemption under the Foreign Agents Registration Act. S. 1762, Foreign Agents Disclosure and Registration Enhancement Act of 2019, provisions relating to the expansion of the Department of Justice's authority to enforce the Foreign Agents Registration Act and increase noncompliance penalties.

H.R. 965 and S. 340, CREATES Act of 2019, provisions relating to improving the process by which generic drug manufacturers could obtain sufficient quantities of brand drug samples for testing thereby deterring practices that impede generic entry to the market. H.R. 938, BLOCKING Act of 2019, provisions relating to discouraging parking of the 180-day exclusivity period for first generic drug manufacturers challenging pharmaceutical patents. H.R. 3, Lower Drug Costs Now Act of 2019, provisions relating to enhancing first generic drug manufacturers' 180-day exclusivity protections, process improvements and new FDA authority concerning generic drug manufacturers' access to reference samples from branded drug manufacturers, and discouraging parking of the 180-day exclusivity period for first generic drug manufacturers challenging pharmaceutical patents. H.R. 19, Lower Costs, More Cures Act of 2019, provisions relating to enhancing first generic drug manufacturers' 180-day exclusivity protections, process improvements and new FDA authority concerning generic drug manufacturers' access to reference samples from branded drug manufacturers, and discouraging parking of the 180-day exclusivity period for first generic drug manufacturers challenging pharmaceutical patents. S. 1895, Lower Health Care Costs Act of 2019, provisions relating to modifications to the exclusivity benefits afforded to first-to-file generic drug manufacturers.

H.R. 965 and S. 340, CREATES Act of 2019, provisions relating to improving the process by which generic manufacturers could obtain sufficient quantities of brand drug samples for testing thereby deterring practices that impede generic entry to the market. H.R. 938, BLOCKING Act of 2019, provisions relating to discouraging parking of the 180-day exclusivity period for first generic drugmakers challenging pharmaceutical patents. S. 1895, Lower Health Care Costs Act of 2019, provisions relating to modifications to the exclusivity benefits afforded to first-to-file generic drugmakers.

H.R. 965 and S. 340 CREATES Act of 2019, provisions relating to improving the process by which generic manufacturers could obtain sufficient quantities of brand drug samples for testing thereby deterring practices that impede generic entry to the market. H.R. 938 BLOCKING Act of 2019, provisions relating to discouraging parking of the 180-day exclusivity period for first generic drugmakers challenging pharmaceutical patents. S. 1895 Lower Health Care Costs Act of 2019, provisions relating to modifications to the exclusivity benefits afforded to first-to-file generic drugmakers. H.R. 990 and S. 344 Hatch-Waxman Integrity Act of 2019, provisions relating to limit generic companies' ability to initiate inter partes review. H.R. 1520 Purple Book Continuity Act, provisions relating to codifying publication of patents of approved biological products in the Purple Book in a similar format and with similar requirements to the Orange Book. H.R. 1503 Orange Book Transparency Act, provisions relating to requiring manufacturers to share complete and timely information with FDA, as well as ensuring that patents listed in the Orange Book are relevant to the approved drug product. H.R. 1499 Protecting Consumer Access to Generic Drugs Act, provisions relating to the prohibition of agreements between brand drug and generic manufacturers that pay generic manufacturers to keep the generic equivalent off the market. H.R. 1781 Payment Commission Data, provisions relating to providing drug pricing and rebate data access the Medicare Payment Advisory Commission and Medicaid and CHIP Payment and Access Commission to help these commissions better understand the true costs of prescription drugs to consumers and taxpayers.

Potential bill that would revise the federal excise tax on commercial truck purchases based on a truck's performance beyond currently applicable emission standards. S. 1094 and H.R. 2256, Driving America Forward Act, provisions relating to the extension of the electric vehicle tax credit. S. 2289 and H.R. 3961, Renewable Energy Extension Act of 2019, provisions relating to extension of tax incentives associated with fuel cell projects.

EPA heavy-duty vehicle criteria pollutant regulation (EPA Cleaner Trucks Initiative). EPA heavy-duty vehicle GHG Phase 2 regulation, provisions relating to glider kits. EPA and NHTSA federal light-duty mobile source regulations, provisions relating to criteria pollutant emission standards, CAFE and greenhouse gas programs, and certification procedures. EPA reconsideration of the 2015 Ozone NAAQS and the 2020 Ozone NAAQS review. H.R. 978, Clean and Efficient Cars Act of 2019, provisions relating to EPA/NHTSA light-duty greenhouse gas and fuel efficiency standards. H.R. 3314, 100 by '50 Act, provisions relating to low-emission commercial truck incentives. S. 92, Regulations from the Executive in Need of Scrutiny Act of 2019, provisions relating to regulatory reform of the Administrative Procedures Act. S. 2302, America's Transportation Infrastructure Act of 2019, provisions relating to Diesel Emissions Reduction Act funding and alternative fuel/recharging infrastructure funding.

EPA heavy-duty vehicle criteria pollutant regulation (EPA Cleaner Trucks Initiative). EPA heavy-duty vehicle GHG Phase 2 regulation, provisions relating to glider kits. EPA and NHTSA federal light-duty mobile source regulations, provisions relating to criteria pollutant emission standards, CAFE and greenhouse gas programs, and certification procedures. EPA reconsideration of the 2015 Ozone NAAQS and the 2020 Ozone NAAQS review. H.R. 978 Clean and Efficient Cars Act of 2019, provisions relating to EPA/NHTSA light-duty greenhouse gas and fuel efficiency standards. S. 92, Regulations from the Executive in Need of Scrutiny Act of 2019, provisions relating to regulatory reform of the Administrative Procedures Act. S. 2302, America's Transportation Infrastructure Act of 2019, provisions relating to Diesel Emissions Reduction Act funding and alternative fuel/recharging infrastructure funding.

United States-Mexico-Canada (USMCA); the Uniform Tariff Schedule (UTS), including USTR's s. 301 investigation into China; Department of Commerce's s. 232 Aluminum and Steel investigation, and s. 232 Auto investigation; and potential tariffs on imports from Mexico.

United States-Mexico-Canada (USMCA); the Uniform Tariff Schedule (UTS), including USTR's s. 301 investigation into China, Department of Commerce's s. 232 Aluminum and Steel investigation, and s. 232 Auto investigation.

United States-Mexico-Canada (USMCA); the Uniform Tariff Schedule (UTS), including USTR's s. 301 investigation into China; Department of Commerce's s. 232 Aluminum and Steel investigation, and s. 232 Auto investigation; and potential tariffs on imports from Mexico.

United States-Mexico-Canada (USMCA); the Uniform Tariff Schedule (UTS), including USTR's s. 301 investigation into China; Department of Commerce's s. 232 Aluminum and Steel investigation, and s. 232 Auto investigation; and potential tariffs on imports from Mexico.

United States-Mexico-Canada (USMCA); the Uniform Tariff Schedule (UTS), including USTR's s. 301 investigation into China, Department of Commerce's s. 232 Aluminum and Steel investigation, and s. 232 Auto investigation.

United States-Mexico-Canada (USMCA); the Uniform Tariff Schedule (UTS), including USTR's s. 301 investigation into China; Department of Commerce's s. 232 Aluminum and Steel investigation, and s. 232 Auto investigation; and potential tariffs on imports from Mexico.

United States-Mexico-Canada (USMCA); the Uniform Tariff Schedule (UTS), including USTR's s. 301 investigation into China; Department of Commerce's s. 232 Aluminum and Steel investigation, and s. 232 Auto investigation; and potential tariffs on imports from Mexico.

United States-Mexico-Canada (USMCA); the Uniform Tariff Schedule (UTS), including USTR's s. 301 investigation into China; Department of Commerce's s. 232 Aluminum and Steel investigation, and s. 232 Auto investigation; and potential tariffs on imports from Mexico.

H.R. 965 and S. 340, CREATES Act of 2019, provisions relating to improving the process by which generic manufacturers could obtain sufficient quantities of brand drug samples for testing thereby deterring practices that impede generic entry to the market. H.R. 938, BLOCKING Act of 2019, provisions relating to discouraging parking of the 180-day exclusivity period for first generic drugmakers challenging pharmaceutical patents. S. 1895, Lower Health Care Costs Act of 2019, provisions relating to modifications to the exclusivity benefits afforded to first-to-file generic drugmakers.

H.R. 965 and S. 340 CREATES Act of 2019, including provisions related to improving the process by which generic manufacturers could obtain sufficient quantities of brand drug samples for testing thereby deterring practices that impede generic entry to the market. H.R. 938 BLOCKING Act of 2019, including provisions related to discouraging parking of the 180-day exclusivity period for first generic companies challenging pharmaceutical patents. H.R. 990 and S. 344 Hatch-Waxman Integrity Act of 2019, including provisions relating to limit generic companies' ability to initiate inter partes review. H.R. 1520 Purple Book Continuity Act, including provisions relating to codifying publication of patents of approved biological products in the Purple Book in a similar format and with similar requirements to the Orange Book. H.R. 1503 Orange Book Transparency Act, including provisions relating to requiring manufacturers to share complete and timely information with FDA, as well as ensuring that patents listed in the Orange Book are relevant to the approved drug product. H.R. 1499 Protecting Consumer Access to Generic Drugs Act, including provisions relating to the prohibition of agreements between brand drug and generic manufacturers that pay generic manufacturers to keep the generic equivalent off the market. H.R. 1781 Payment Commission Data, including provisions relating to providing drug pricing and rebate data access the Medicare Payment Advisory Commission and Medicaid and CHIP Payment and Access Commission to help these commissions better understand the true costs of prescription drugs to consumers and taxpayers.

H.R. 965 and S. 340 CREATES Act of 2019, provisions relating to improving the process by which generic manufacturers could obtain sufficient quantities of brand drug samples for testing thereby deterring practices that impede generic entry to the market. H.R. 938 BLOCKING Act of 2019, provisions relating to discouraging parking of the 180-day exclusivity period for first generic drugmakers challenging pharmaceutical patents. S. 1895 Lower Health Care Costs Act of 2019, provisions relating to modifications to the exclusivity benefits afforded to first-to-file generic drugmakers. H.R. 990 and S. 344 Hatch-Waxman Integrity Act of 2019, provisions relating to limit generic companies' ability to initiate inter partes review. H.R. 1520 Purple Book Continuity Act, provisions relating to codifying publication of patents of approved biological products in the Purple Book in a similar format and with similar requirements to the Orange Book. H.R. 1503 Orange Book Transparency Act, provisions relating to requiring manufacturers to share complete and timely information with FDA, as well as ensuring that patents listed in the Orange Book are relevant to the approved drug product. H.R. 1499 Protecting Consumer Access to Generic Drugs Act, provisions relating to the prohibition of agreements between brand drug and generic manufacturers that pay generic manufacturers to keep the generic equivalent off the market. H.R. 1781 Payment Commission Data, provisions relating to providing drug pricing and rebate data access the Medicare Payment Advisory Commission and Medicaid and CHIP Payment and Access Commission to help these commissions better understand the true costs of prescription drugs to consumers and taxpayers.